Papers in the journal European Urology (Page 2)

#21

JOURNAL ARTICLE

Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): A Pooled Analysis of Five Randomized Trials from the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium.

Wee Loon Ong, Tahmineh Romero, Soumyajit Roy, John Nikitas, David Joseph, Almudena Zapatero, Shawn Malone, Scott C Morgan, Michael L Steinberg, Luca F Valle, Nicholas G Zaorsky, Ting Martin Ma, Matthew B Rettig, Nicholas Nickols, Tommy Jiang, Robert E Reiter, Sriram V Eleswarapu, Xavier Maldonado, Yilun Sun, Paul L Nguyen, Jeremy L Millar, Jarad M Martin, Daniel E Spratt, Amar U Kishan

BACKGROUND AND OBJECTIVE: Time to testosterone recovery (TR) following androgen deprivation therapy (ADT) with gonadotropin-releasing hormone agonists varies widely. We evaluate TR kinetics and the oncological impact of an effective castration period in patients receiving definitive radiotherapy and ADT for prostate cancer. METHODS: We obtained individual patient data from randomized controlled trials of radiotherapy with ADT and prospectively collected serial testosterone data from the MARCAP Consortium...

39304428

September 19, 2024: European Urology

#22

JOURNAL ARTICLE

Prostate Cancer-related Events in Patients with Synchronous Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate; Data from the HORRAD Trial.

Liselotte M S Boevé, Maarten C C M Hulshof, Paul C M S Verhagen, Jos W R Twisk, Wim P J Witjes, Peter de Vries, R Jeroen A van Moorselaar, André N Vis, George van Andel

BACKGROUND AND OBJECTIVE: A survival benefit was demonstrated for patients with low-volume synchronous metastatic hormone-sensitive prostate cancer (mHSPCa) when local radiotherapy to the prostate was added to androgen deprivation therapy. This study aims to determine the incidence of prostate cancer-related events and treatments in those who received and those who did not receive external beam radiotherapy for mHSPCa. METHODS: The HORRAD trial is a multicentre randomised controlled trial recruiting originally 432 patients with mHSPCa diagnosed between 2004 and 2014...

39304427

September 19, 2024: European Urology

#23

REVIEW

Prostate Cancer Therapy Cardiotoxicity Map (PROXMAP) for Advanced Disease States: A Systematic Review and Network Meta-analysis with Bayesian Modeling of Treatment Histories.

Moez Karim Aziz, Donald Molony, Dominique Monlezun, Travis Holder, Oliver Brunckhorst, Noel Higgason, Jerry Roland, Resa Magill, Mariya Fatakdawala, Alexander Iacobucci, Neal Mody-Bailey, Chris Owen, Andrew Zarker, Emma Thames, Justin Swaby, Daniel Xiao, Lily Choi, Shubh Desai, Jacob Galan, Brett Deng, Taylor Hartshorne, Alexis Nichols, Allan Zhang, Jared Imber, Jeffrey Song, William Jones, Alexis Rivas, Darren Sanchez, Maya Guhan, Giorgio Gandaglia, Shreyas Ranganath, Jerril Jacob, Skyler Howell, Juan Plana, Roderick van den Bergh, Matthew Roberts, Silke Gillessen Sommer, Jan Oldenburg, Guillaume Ploussard, Derya Tilki, Ivo Schoots, Erik Briers, Johan Stranne, Olivier Rouviere, Inge van Oort, Daniela Oprea-Lager, Maria De Santis, Philip Cornford

BACKGROUND AND OBJECTIVE: Recommendations of first-line therapies for metastatic hormone-sensitive (mHSPC), nonmetastatic castrate-resistant (M0CRPC), and metastatic castrate-resistant (mCRPC) prostate cancer do not account for cardiotoxicity due to a lack of clear prior evidence. This manuscript assesses cardiotoxicity of these therapies. METHODS: We searched Ovid Medline, Elsevier Embase, and the Cochrane Library for randomized clinical trials (RCTs) from database inception to January 14, 2024...

39299896

September 18, 2024: European Urology

#24

JOURNAL ARTICLE

Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate Cancer.

Adam B Weiner, Raag Agrawal, Nicholas K Wang, Ida Sonni, Eric V Li, Jaron Arbet, J J H Zhang, James A Proudfoot, Boon Hao Hong, Elai Davicioni, Nathanael Kane, Luca F Valle, Amar U Kishan, Alan Dal Pra, Pirus Ghadjar, Christopher J Sweeney, Nicholas G Nickols, R Jeffrey Karnes, John Shen, Matthew B Rettig, Johannes Czernin, Ashely E Ross, Melvin Lee Kiang Chua, Edward M Schaeffer, Jeremie Calais, Paul C Boutros, Robert E Reiter

BACKGROUND AND OBJECTIVE: We characterized tumor prostate-specific membrane antigen (PSMA) levels as a reflection of cancer biology and treatment sensitivities for treatment-naïve prostate cancer. METHODS: We first correlated PSMA positron emission tomography (PET) maximum standardized uptake values (SUVmax) in primary prostate cancer with tumor FOLH1 (PSMA RNA abundance) to establish RNA as a proxy (n = 55). We then discovered and validated molecular pathways associated with PSMA RNA levels in two large primary tumor cohorts...

39294048

September 17, 2024: European Urology

#25

LETTER

Reply to Rongkang Li, Lei Peng, Shaohua Zhang, and Song Wu's Letter to the Editor re: Johan Bjerner, Ola Bratt, Kirsti Aas, et al. Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the Norwegian Prostate Cancer Consortium. Eur Urol 2024;86:20-6.

Johan Bjerner, Ola Bratt, Kirsti Aas, Peter C Albertsen, Sigrid V Carlsson, Jan Oldenburg

No abstract text is available yet for this article.

39294047

September 17, 2024: European Urology

#26

EDITORIAL

Prostate Cancer Screening: Setting the Controls on the Mixing Board.

Ola Bratt

No abstract text is available yet for this article.

39294046

September 17, 2024: European Urology

#27

JOURNAL ARTICLE

Hypofractionated Dose Escalation Radiotherapy for High-risk Prostate Cancer: The Survival Analysis of the Prostate Cancer Study 5, a Groupe de Radio-oncologie Génito-urinaire du Quebec-led Phase 3 Trial.

Tamim Niazi, Abdenour Nabid, Talia Malagon, Steven Tisseverasinghe, Redouane Bettahar, Rafika Dahmane, Andre-Guy Martin, Marjory Jolicoeur, Michael Yassa, Maroie Barkati, Levon Igidbashian, Boris Bahoric, Robert Archambault, Hugo Villeneuve, Md Mohiuddin

BACKGROUND AND OBJECTIVE: Prostate Cancer Study 5 (PCS5) compared conventional fractionated radiotherapy (CFRT) with hypofractionated radiotherapy (HFRT) in high-risk prostate cancer (PCa) patients, hypothesizing similar toxicity and survival outcomes. This report presents the efficacy analysis. METHODS: PCS5 is a Canadian multicenter, open-label, phase 3 randomized control trial. Men with histologically proven, clinically localized PCa with one or more high-risk features (T3/T4, Gleason score ≥8, and prostate-specific antigen >20) were eligible...

39271420

September 12, 2024: European Urology

#28

JOURNAL ARTICLE

Abdominal Noncontrast Computed Tomography Scanning to Screen for Kidney Cancer and Other Abdominal Pathology Within Community-based Computed Tomography Screening for Lung Cancer: Results of the Yorkshire Kidney Screening Trial.

Grant D Stewart, Angela Godoy, Fiona Farquhar, Jessica Kitt, Jon Cartledge, Michael Kimuli, Sabrina H Rossi, Bethany Shinkins, Simon Burbidge, Sarah W Burge, Iztok Caglic, Emma Collins, Philip A J Crosbie, Claire Eckert, Sheila Fraser, Neil Hancock, Gareth R Iball, Catriona Marshall, Golnessa Masson, Richard D Neal, Suzanne Rogerson, Andrew Smith, Stephen J Sharp, Irene Simmonds, Tom Wallace, Matthew Ward, Matthew E J Callister, Juliet A Usher-Smith

BACKGROUND AND OBJECTIVE: The Yorkshire Kidney Screening Trial (YKST) assessed the feasibility of adding abdominal noncontrast computed tomography (NCCT) to lung cancer screening to screen for kidney cancer and other abdominal pathology. METHODS: A prospective diagnostic study offered abdominal NCCT to 55-80-yr-old ever-smokers attending a UK randomised lung cancer screening trial (May 2021 to October 2022). The exclusion criteria were dementia, frailty, previous kidney/lung cancer, and computed tomography (CT) of the abdomen and thorax within previous 6 and 12 mo, respectively...

39271419

September 12, 2024: European Urology

#29

JOURNAL ARTICLE

Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial.

Nicholas van As, Binnaz Yasar, Clare Griffin, Jaymini Patel, Alison C Tree, Peter Ostler, Hans van der Voet, Daniel Ford, Shaun Tolan, Paula Wells, Rana Mahmood, Mathias Winkler, Andrew Chan, Alan Thompson, Chris Ogden, Olivia Naismith, Julia Pugh, Georgina Manning, Stephanie Brown, Stephanie Burnett, Emma Hall

BACKGROUND AND OBJECTIVE: Randomised data on patient-reported outcomes (PROs) for stereotactic body radiotherapy (SBRT) and prostatectomy in localised prostate cancer are lacking. PACE-A compared patient-reported health-related quality of life after SBRT with that after prostatectomy. METHODS: PACE is a phase 3 open-label, randomised controlled trial. PACE-A randomised men with low- to intermediate-risk localised prostate cancer to SBRT or prostatectomy (1:1). Androgen deprivation therapy (ADT) was not permitted...

39266383

September 11, 2024: European Urology

#30

EDITORIAL

Tissue-based Biomarkers Steering Clinical Decisions in Patients with Urothelial Cancer.

Luca Afferi, Alessia Cimadamore, Andrea Gallioli, Benjamin Pradere, Laura S Mertens, Gautier Marcq, Georgia Anguera, Andrea Necchi, Alberto Briganti, Francesco Montorsi, Morgan Rouprêt, Paolo Gontero, Alberto Breda, Marco Moschini

The European Association of Urology (EAU), National Comprehensive Cancer Network, and European Society for Medical Oncology guidelines recommend PD-L1 and FGFR testing for patients with locally advanced bladder cancer or upper tract urothelial cancer (UTUC) according to specific eligibility criteria; positive results indicate therapy with immune checkpoint inhibitors or erdafitinib, respectively. The EAU guidelines recommend PD-L1 testing for subsequent adjuvant therapy in high-risk UC, and germline DNA sequencing in patients with UTUC positive for DNA mismatch repair alterations...

39266382

September 11, 2024: European Urology

#31

LETTER

Re: Johan Bjerner, Ola Bratt, Kirsti Aas, et al. Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the Norwegian Prostate Cancer Consortium. Eur Urol 2024;86:20-6.

Rongkang Li, Lei Peng, Shaohua Zhang, Song Wu

No abstract text is available yet for this article.

39242324

September 5, 2024: European Urology

#32

JOURNAL ARTICLE

Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [ 177 Lu]Lu-PSMA-617 in the Phase 3 VISION Trial.

Andrew J Armstrong, Oliver Sartor, Johann de Bono, Kim Chi, Karim Fizazi, Bernd J Krause, Ken Herrmann, Kambiz Rahbar, Scott T Tagawa, Fred Saad, Tomasz M Beer, Jiwen Wu, Osvaldo Mirante, Michael J Morris

BACKGROUND AND OBJECTIVE: The prognostic value of declining prostate-specific antigen (PSA) levels is under investigation in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) receiving PSMA-targeted radioligand therapy with [177 Lu]Lu-PSMA-617 (177 Lu-PSMA-617). This post hoc analysis of the phase 3 VISION trial aimed to evaluate associations between PSA decline and clinical and patient-reported outcomes in patients receiving 177 Lu-PSMA-617...

39242323

September 5, 2024: European Urology

#33

LETTER

Weight Change and All-cause Mortality in a Population-based Study of Nonmetastatic Renal Cell Carcinoma.

Carolyn E Eberle, Linnea T Olsson, Helena Furberg, Whitney R Robinson

No abstract text is available yet for this article.

39232982

September 3, 2024: European Urology

#34

LETTER

A Novel Artificial Intelligence-powered Tool for Precise Risk Stratification of Prostate Cancer Progression in Patients with Clinical Intermediate Risk.

Sujit S Nair, Hassan Muhammad, Parag Jain, Chensu Xie, Ina Pavlova, Rachel Brody, Wei Huang, Maria Nakadar, Xiangfu Zhang, Hirak Basu, George Wilding, Rajat Roy, Dimple Chakravarty, Ashutosh K Tewari

No abstract text is available yet for this article.

39232981

September 3, 2024: European Urology

#35

EDITORIAL

Further Randomized Data Confirming Minimal Benefit from the Addition of Hormone Therapy to Postoperative Radiotherapy.

Daniel E Spratt

No abstract text is available yet for this article.

39232980

September 3, 2024: European Urology

#36

REVIEW

VISION: An Individual Patient Data Meta-analysis of Randomised Trials Comparing Magnetic Resonance Imaging Targeted Biopsy with Standard Transrectal Ultrasound Guided Biopsy in the Detection of Prostate Cancer.

Veeru Kasivisvanathan, Vinson Wai-Shun Chan, Keiran D Clement, Brooke Levis, Alexander Ng, Aqua Asif, Masoom A Haider, Mark Emberton, Gregory R Pond, Ridhi Agarwal, Katie Scandrett, Yemisi Takwoingi, Laurence Klotz, Caroline M Moore

BACKGROUND AND OBJECTIVE: The PRECISION and PRECISE trials compared magnetic resonance imaging targeted biopsy (MRI ± TB) with the standard transrectal ultrasound (TRUS) guided biopsy for the detection of clinically significant prostate cancer (csPCa). PRECISION demonstrated superiority of MRI ± TB over TRUS guided biopsy, while PRECISE demonstrated noninferiority. The VISION study is a planned individual patient data meta-analysis (IPDMA) comparing MRI ± TB with TRUS guided biopsy for csPCa diagnosis...

39232979

September 3, 2024: European Urology

#37

REVIEW

Clinical Implications of Basic Research: Exploring the Transformative Potential of Spatial 'Omics in Uro-oncology.

Sandy Figiel, Anthony Bates, David A Braun, Renu Eapen, Markus Eckstein, Brandon J Manley, Matthew I Milowsky, Tom J Mitchell, Richard J Bryant, John P Sfakianos, Alastair D Lamb

New spatial molecular technologies are poised to transform our understanding and treatment of urological cancers. By mapping the spatial molecular architecture of tumours, these platforms uncover the complex heterogeneity within and around individual malignancies, offering novel insights into disease development, progression, diagnosis, and treatment. They enable tracking of clonal phylogenetics in situ and immune-cell interactions in the tumour microenvironment. A whole transcriptome/genome/proteome-level spatial analysis is hypothesis generating, particularly in the areas of risk stratification and precision medicine...

39227262

September 2, 2024: European Urology

#38

JOURNAL ARTICLE

Re: International Survey on Urodynamic Investigations in Women Undergoing Stress Urinary Incontinence Surgery.

Maurizio Serati, Tufan Tarcan, Enrico Finazzi Agrò

No abstract text is available yet for this article.

39227261

September 2, 2024: European Urology

#39

LETTER

Reply to Andrés Gutiérrez, Julio Cesar Boada, and Sebastián Peña's Letter to the Editor re: Pieter Vynckier, Lieven Annemans, Sarah Raes, et al. Systematic Review on the Cost-effectiveness of Prostate Cancer Screening in Europe. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.04.036.